Seneca Biopharma, Inc. CUR Cash Flow

Seneca biopharma, inc. (CUR)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-7,575	-2,037	-1,763	-1,436	-3,113	-320	-1,830	-627	-2,146	-3,315	-133	-4,649	-7,567	-5,396	-5,220	-3,852	-6,605	-4,765	-5,637	-5,448	-5,053	-5,503	-4,455	-6,751	-5,919	-3,303	-6,686	-6,251	-3,590	-2,714	-2,577	-2,376	-2,452	-2,556	-3,211	-3,648	-3,101
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization
29	30	36	37	39	25	46	46	67	55	53	68	112	62	97	92	85	90	88	83	83	88	83	86	90	62	81	50	50	46	87	41	34	37	64	59	25
Share-based compensation expense
75	119	294	128	337	63	134	196	238	265	329	651	522	578	578	817	1,470	830	805	625	689	681	656	541	2,440	250	1,007	596	476	423	486	330	370	458	667	1,058	1,148
Warrant inducement expense
5,620	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred financing fees and debt discount
-	-	-	-	-	-	-	-	-	0	0	12	47	63	79	14	189	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred financing fees and debt discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	207	190	207	224	231	223	216	22	0	0	0	0	-	-	-	-
Warrant modification expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,945	2,405	666	0	0	0	0	-	-	-	-
Gain from change in fair value of warrant obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	334	105	677	188	-6	-	-	-	-	-	-	-	-
(Gain) loss on fair value of liability classified warrants
24	82	320	436	-340	1,463	236	1,378	190	-1,067	2,679	-341	-2,741	441	-538	757	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant inducement expense
-	-	-	-	-	-	-	-	-	0	0	87	476	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Expenses related to issuance of liability classified warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	466	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred financing fees and debt discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	215	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Gain from change in fair value of derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	161
Trade and other receivables
-2	-40	-108	-67	-56	132	-316	341	-175	275	32	-9	4	-2	7	-34	1	18	0	10	-217	192	8	13	1	2	-49	-47	100	2	-56	-177	0	-	-	-	-
Related party receivable
-	-	-	0	-362	9	9	8	-89	10	10	10	-84	12	465	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
-93	-93	349	-37	-75	-186	197	12	-56	-146	308	-237	-221	-300	178	-309	-82	-131	385	516	71	-135	2	-123	64	-86	5	-62	18	-46	17	-74	-61	-78	172	-71	5
ROU and other assets
-9	-	-	-	-19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-6	6	-322
Other assets
-	-	-	-	-	-	-	0	4	0	0	-2	0	-34	-7	0	-14	-0	15	-1	0	0	-1	-5	0	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-133	140
Accounts payable and accrued expenses
138	-356	132	-35	244	-11	126	-444	293	-602	-759	66	-227	-150	74	-215	1,170	-	-	-	-	-	-	-	-	-	492	-672	-11	-	352	-505	-189	449	621	-37	-144
Accrued bonuses
-36	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-375	483	284	122	492	-	-	-	-	-	-	-	-	-	-	-	-
Accrued bonuses
-	-	-	-	-	-	-	0	-418	418	0	0	-852	852	0	-287	125	-606	277	265	-421	-	-	158	-307	-	-	-	-	-13	159	-196	74	43	158	158	-230
Other current liabilities
1	0	8	-28	-27	-14	-15	49	-7	-34	-22	-185	12	16	20	-107	49	55	58	142	-3	-5	1	0	0	21	-19	0	0	-	-	-	0	-	-	-	-
Lease and other long term liabilities
-9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long term liabilities
-	-	-	-	-	-	-	-2	-0	-1	-0	-11	-2	-2	-1	-84	-67	-56	-56	-138	0	-0	-2	-3	-3	-3	-3	-2	-2	-	-	-	0	-	-	-	-
Net cash used in operating activities
-1,677	-2,048	-1,897	-1,643	-1,665	-1,658	-1,663	-2,523	-1,846	-2,286	-3,322	-3,371	-4,435	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,420	-2,438	-2,100	-	-1,813	-2,211	-2,288
Cash flows from investing activities:
Purchases of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,500	-10,014	0	15,032	0	10,007	0	15,000	0	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,571	-3,488	-3,899	-5,508	-4,804	-4,719	-3,480	-3,101	-2,412	-2,712	-2,475	-2,243	-3,359	-2,512	-	-	-	-	-	-	-	-
Maturity of short-term investments
-	-	-	-	-	0	0	0	5,000	0	0	5,000	0	0	0	0	7,517	0	0	0	15,007	0	10,000	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Patent costs
-	-	-	-	-	-	-	-	-	-	-	-	-	32	0	17	12	5	-8	12	57	40	60	135	112	85	93	137	95	57	38	91	28	51	127	61	44
Purchase of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	83	14	48	32	79	16	35	27	34	111	6	113	3	1	9	0	29	0	9	5	131	50
Net cash provided by investing activities
-	-	-	-	-	-1	0	0	5,000	-0	-0	-93	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38	-120	-28	-	-132	-192	-94
Cash flows from financing activities:
Net cash (used in) provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-100	7,490	-2,553	9,991	-92	-98	-76	-95	-169	-15,223	-92	-207	-140	-96	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock from warrants exercised, net of issuance costs
-	-	-	-	-	-	-	-	-	0	218	806	2,200	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from the sale of common stock and warrants
-	-	-	-	-	-	-	-	-	0	5,413	47	50	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from warrant exercises
6,732	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of fees related to prior financing
-	-	-	-	-	-	-	-	-	-	-	-	11	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of taxes on stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	426	0	0	0	0	-	-	-	-	-	-	-	-
Proceeds from long-term debt transactions, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	7,551	0	0	0	0	-	-	-	-
Payments of long-term debt
-	-	-	-	-	-	-	-	-	0	0	2,543	1,222	1,187	1,155	1,129	1,096	1,154	0	0	0	12	492	720	704	0	0	0	0	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock from warrants exercised, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,073	133	10	259	1,391	271	3,439	2,074	322	204	0	0	0	0	-0	0	1,668
Proceeds from issuance of common stock from options exercised
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	20	113	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from sale of common stock and warrants, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,931	-0	414	-47	19,101	2,807	4,241	0	0	0	8,808	-45	4,921	-	-	-	-
Payment on fees for future financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0	0	42	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payments of short-term note payable
138	136	45	78	117	115	38	105	104	103	34	95	94	124	0	0	0	0	0	46	70	70	23	40	40	101	0	32	48	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
6,593	-136	6,922	-78	-117	1,712	311	-105	-104	-103	5,945	-1,773	921	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,792	-45	4,921	-	-0	0	1,668
Payments on Note Payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16	0	0	-	-	-	-
Net cash (used in ) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,179	-1,096	-1,958	0	-46	5,892	4,130	-90	-528	19,433	3,011	7,680	2,007	7,825	-	-	-	-	-	-	-	-
Effects of exchange rates on cash
-0	0	-6	-1	0	-2	-3	-2	0	0	-1	-0	-0	-1	0	0	-0	-2	-1	-0	0	-0	0	0	-1	-	-	-	-	-	-	-	-	-	-	-	-
Effects of exchange rates on cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
4,915	-2,184	5,018	-1,723	-1,782	50	-1,355	-2,631	3,049	-2,388	2,621	-5,238	-3,514	9,518	-5,452	3,508	2,904	-8,414	4,481	-4,944	1,074	573	-3,287	-3,110	1,496	444	5,235	-1,493	5,215	-2,429	7,333	-2,604	2,792	-1,843	-1,946	-2,404	-714
Supplemental disclosure of cash flows information:
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	150	513	205	230	242	243	238	189	175	183	214	224	224	174	0	0	0	0	0	-	-	-	-
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Cash paid for interest
2	4	1	0	2	3	1	0	1	3	-24	2	136	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Extinguishment of warrant obligations through exercise, expiration and modification
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,089
Issuance of common stock for cashless exercise of options, warrants and RSUs
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-29	38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for cashless exercise of warrants and options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	201	0	3	130	1,073	-	-	-	-	-	-	-	-	-	-	-	-
Prepayment of services through warrant issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	-	-	-	-	-	-	-	-
Issuance of common stock for cashless exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	587	0	0	-	-	-	-	-	-	-	-
Issuance of common stock for cashless exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Issuance of common stock for fees related to debt issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	396	-	-	-	-	-	-	-	-
Prepayment of services through common stock issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	180	-	-	-	-
Prepayment of services through warrant issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of common stock for fees related to debt issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of warrants for fees related to debt issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	452	-	0	0	0	-	-	-	-
Issuance of common stock from executive bonuses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77